Clinical Trial Update: Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing irinotecan liposome injection–containing regimens against nab-paclitaxel plus gemcitabine in previously untreated metastatic pancreatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer Metastatic
• Pancreatic Cancer Non-resectable

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Irinotecan liposome injection-containing regimens (irinotecan liposome injection)
• Nab-paclitaxel plus gemcitabine (nab-paclitaxel)

Snippet

Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. | Conditions: Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | Phase 2 | Status: UNKNOWN